Healthcare Professionals

Media Library

Early detection of ovarian cancer is critical to patient survival. Unfortunately, most women do not present with symptoms until the disease has already progressed to later stages, decreasing their chances of being cured of the disease. However, the new HE4 + CA125 biomarker combination has shown an increased sensitivity and specificity for detection of early stage ovarian cancer in patients with a pelvic mass over that of CA125 alone.

WEBINARS

Watch either webinar to learn more about the utility and limitations of existing assessment tools including ultrasound and biomarkers, how ROMA (HE4 + CA125 + menopausal status) can aid in pelvic mass risk assessment, and which women should be referred to a gynecologic oncologist and/or tertiary care facility for surgery.


Webinar: Dr. Kevin Holcomb

Dr. Kevin Holcomb, M.D.
Dr. Kevin Holcomb discusses current ovarian cancer techniques and guidelines, and the role of ROMA™ (Risk of Ovarian Malignancy Algorithm) in aiding risk stratification of patients with a pelvic mass.





Webinar: Dr. Barbara A. Goff

Dr. Barbara A. Goff, M.D.
Dr. Barbara Goff discusses current ovarian cancer techniques and guidelines, and the role of ROMA™ (Risk of Ovarian Malignancy Algorithm) in aiding risk stratification of patients with a pelvic mass.

VIDEOS

Watch this selection of videos below to learn more about ovarian cancer, the use of CA125 + HE4 for likelihood stratification, and the importance of referring high-likelihood patients to tertiary care centers.

Video: Richard G. Moore, M.D., FACOG, FACS

Richard G. Moore, M.D., FACOG, FACS - 1:04
Dr. Richard Moore, MD, FACOG, FACS discusses the prevalence of ovarian cancer, the challenges of diagnosing and treating patients, and the importance of early detection.

Video: Richard G. Moore, M.D., FACOG, FACS explains the research

Richard G. Moore, M.D., FACOG, FACS explains the research - 1:17
Understand the research that led to the discovery of the CA125 + HE4 biomarker combination, and find out how the addition of HE4 to CA125 improves the ability to detect ovarian cancer.

Video: Richard G. Moore, M.D., FACOG, FACS discusses CA125 + HE4

Richard G. Moore, M.D., FACOG, FACS discusses CA125 + HE4 - 1:18
What are CA125 and HE4? Learn more about these important biomarkers and how they work together to improve early detection of ovarian cancer from Richard G. Moore, M.D., FACOG, FACS

Video: The CA125 + HE4 differential diagnostic test reviewed by Richard G. Moore, M.D., FACOG, FACS

The CA125 + HE4 differential diagnostic test reviewed by Richard G. Moore, M.D., FACOG, FACS - 1:03
Find out how the breakthrough CA125 + HE4 differential diagnostic test can help stratify patients by likelihood and determine the best course of care from Richard G. Moore, M.D., FACOG, FACS

Video: Dierdre Maguire

Dierdre Maguire - 2:44
Dierdre Maguire, an ovarian cancer patient, discusses her diagnosis and treatment.

Video: Terrie Pancio

Terrie Pancio - 2:19
Ovarian cancer survivor Terrie Pancio shares her experience with diagnosis, treatment, and remission.